Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)
about
hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicineInduced pluripotent stem cells as a disease modeling and drug screening platformInduced pluripotent stem cell models of lysosomal storage disorders.Number of polyploid giant cancer cells and expression of EZH2 are associated with VM formation and tumor grade in human ovarian tumor.Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biologyInduced pluripotent stem cells--opportunities for disease modelling and drug discovery.Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds.Induced pluripotent stem cells for modelling human diseasesRescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model.Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type AImplications of aneuploidy for stem cell biology and brain therapeuticsGeneration of neuronal progenitor cells and neurons from mouse sleeping beauty transposon-generated induced pluripotent stem cellsNew lessons learned from disease modeling with induced pluripotent stem cells.Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseasesIn vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.Induced pluripotent stem cells as a next-generation biomedical interface.Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo.Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines.Disease models for the development of therapies for lysosomal storage diseases.Daughter Cells and Erythroid Cells Budding from PGCCs and Their Clinicopathological Significances in Colorectal CancerPatient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosaReprogramming cellular identity for regenerative medicine.Prospect of induced pluripotent stem cell genetic repair to cure genetic diseases.Mesodermal and hematopoietic differentiation from ES and iPS cells.Gene, stem cell, and future therapies for orphan diseases.Treatment options for lysosomal storage disorders: developing insights.Concise Review: Patient-Derived Stem Cell Research for Monogenic Disorders.Human-Induced Pluripotent Stem Cell-Based Modeling of Cardiac Storage Disorders.Glycosylation and stem cells: Regulatory roles and application of iPSCs in the study of glycosylation-related disorders.The promise of human induced pluripotent stem cells in dental research.Quaking Is a Key Regulator of Endothelial Cell Differentiation, Neovascularization, and Angiogenesis.Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy.CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks.Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification.Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.Impaired Hematopoiesis and Disrupted Monocyte/Macrophage Homeostasis in Mucopolysaccharidosis Type I Mice.Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls.Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy.
P2860
Q26751506-7DFE4BBA-B825-45AE-A454-5E640E9AD928Q26865689-CBA59641-BCB5-4D05-BE9E-C4B063ECE1CDQ33830512-23C83331-4D7A-400B-A0EB-2160B76EEC04Q33849806-3F60B1A6-575B-422C-A7A7-5F01DE4B4BCAQ33877155-57D1C0F6-CE88-4EBE-9711-2C831B924D5FQ34231818-099153ED-54C4-40DE-BB81-27D183AB11E0Q34464236-370FAE55-BD87-4E7F-A840-302C4D6CF912Q35088519-3C873A43-0BCC-419B-B24D-2E3DDA4CB860Q35637089-E917BD03-D710-4AB8-9198-01F8E72C4B9DQ35930603-CA36A2DA-6EFF-4C9F-8676-E7224FD20E9DQ36093032-20DCF6B3-24ED-4FE9-8BB8-5B7639777324Q36208256-AE300BA8-A4E0-4536-8B29-9E153F977BC2Q36281888-3DC6A461-0493-4551-BC35-D93691B1A9A6Q36374130-8E31AAFE-5834-42B4-B56F-6E0A914FA79BQ36633022-8FA75EF0-7280-4B0C-B8C0-2D03F684D405Q37005193-4056F4A8-286A-4875-90F8-F6DC3E953E3CQ37055318-156CC86F-EBF1-4AC5-A8E5-CB6243E8F243Q37141535-28886990-DDE3-4D87-AECA-1240C10FDDF0Q37186456-6F2F4CF0-3390-4DE0-A112-A0FCA24C8FC6Q37619231-C91ADE2A-FB23-40FD-8710-3C6F5F5A7419Q37675997-3192B377-A444-4B40-A926-D2C3205A5A25Q37707008-7F27D3A3-C40E-4A31-AE16-972FCA263BC7Q37994281-771F1880-7657-4E35-81A6-D8942D3C1296Q37997007-AA2A9574-B631-45BE-8877-7B45E069B1B3Q38017612-8958910E-4AA5-4C43-8B8D-208DB63CCF9DQ38022126-A0F10698-1FAA-4733-874F-DCDBEF511251Q38046227-7892C78C-0888-448A-BED1-1B875E2F6D29Q38557791-CA40ABE4-712F-42D8-B5C1-54E9FC6DC3ABQ38751652-FC95B0C3-F63C-4A65-A4A3-E469051222E6Q38964383-B6A58A1C-4891-45A3-9BB3-5E7443FC6CAAQ41901236-91DD917D-3E96-4698-842C-A322F9C178F8Q42091587-A87A36AF-9665-4E7A-B528-275DAEB5117DQ42145545-497F2F11-33FA-4F99-9084-2E7ED0C379F5Q42391311-04BAC685-8973-4442-A2F2-404EF763BCB2Q42577149-32B339BA-055A-4DC0-B746-9C48A2B34C18Q42817633-F4BB3D04-1A1F-475C-8766-2472FDDC7C9BQ52598187-27AD93AF-E832-4E63-ACD6-9C8728C3F401Q52662405-CCBA72C6-B4FD-4F2B-A297-7EB260AED059Q53143040-E46A4D52-B7CE-45C5-9903-9CECB7B5BC8CQ55194774-615A7958-04B8-4894-9EBA-F02E570C4D12
P2860
Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome)
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@ast
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@en
Hematopoietic differentiation ...... h mucopolysaccharidosis type I
@nl
type
label
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@ast
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@en
Hematopoietic differentiation ...... h mucopolysaccharidosis type I
@nl
prefLabel
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@ast
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@en
Hematopoietic differentiation ...... h mucopolysaccharidosis type I
@nl
P2093
P2860
P4510
P50
P1433
P1476
Hematopoietic differentiation ...... dosis type I (Hurler syndrome)
@en
P2093
Beau Webber
Brandon Peacock
Chris J Lees
Cindy R Eide
In-Hyun Park
John E Wagner
Mark J Osborn
Paul J Orchard
Ron T McElmurry
P2860
P304
P356
10.1182/BLOOD-2010-05-287607
P407
P577
2010-10-29T00:00:00Z